This trial is testing a new cancer drug combo to see if it's more effective than the current standard of care, in patients who have never smoked.
- Lung Adenocarcinoma
- Non-Small Cell Lung Cancer
2 Primary · 3 Secondary · Reporting Duration: Through study completion, an average of 2 years
2 Treatment Groups
Pemetrexed and Carboplatin (Standard of Care)
1 of 2
LP-300 in Combination with Pemetrexed and Carboplatin
1 of 2
90 Total Participants · 2 Treatment Groups
Primary Treatment: LP-300 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this research endeavor taking on new participants presently?
"Data on clinicaltrials.gov indicates that recruitment for this medical trial is currently underway, with the initial posting being made on August 12th 2022 and most recent update occurring 16 days later." - Anonymous Online Contributor
How many individuals are being included as part of this research endeavor?
"Indeed, the information on clinicaltrials.gov confirms this trial is still recruiting candidates. It was first published on August 12th 2022 and revised most recently on September 16th 2022. The investigators are seeking 90 volunteers to participate in this study at two distinct sites." - Anonymous Online Contributor
Has the FDA authorized LP-300 as a treatment option?
"LP-300's safety rating stands at 2 due to the Phase 2 trial data, which has not yet shown efficacy but does offer evidence of its security." - Anonymous Online Contributor